Research progress of hepatic arterial infusion chemotherapy with FOLFOX regimen

doi:10.3969/j.issn.1009-976X.2023.04.011

Abstract

Abstract: Hepatic arterial infusion chemotherapy （HAIC） is one of the important treatments for hepatocellular carcinoma. In recent years, through continuous exploration, Chinese scholars have innovatively applied the oxaliplatin-based FOLFOX regimen to perfusion chemotherapy for hepatocellular carcinoma, and FOLFOX-HAIC and its combination regimen have achieved encouraging results in the treatment of intermediate to advanced hepatocellular carcinoma, which has received increasing attention. This paper summarizes and analyzes the results reported in the relevant domestic and international literature, and reviews the development history, clinical applications, research progress and current problem of FOLFOX-HAIC.

Key words: hepatocellular carcinoma, hepatic artery infusion chemotherapy, FOLFOX, combination therapy, oxaliplatin

摘要： 肝动脉灌注化疗（HAIC）是肝癌的重要治疗手段之一。近年来中国学者通过不断探索,创新性地将以奥沙利铂为基础的FOLFOX方案应用于肝癌灌注化疗中,FOLFOX-HAIC及其联合方案在治疗中晚期肝癌中取得了令人鼓舞的成果,得到越来越多的重视。本文总结分析国内外相关文献报道,对FOLFOX-HAIC的发展历史、临床应用、研究进展及目前存在的问题等方面进行综述。

关键词: 原发性肝癌, 肝动脉灌注化疗, FOLFOX方案, 联合治疗, 奥沙利铂

CLC Number:

R735.7

QIAN Jun-lin, TANG Hong-tao, LIN Wei, HU Ze-min. Research progress of hepatic arterial infusion chemotherapy with FOLFOX regimen[J]. Lingnan Modern Clinics In Surgery, 2023, 23(04): 347-352.

钱均霖, 汤宏涛, 林葳, 胡泽民. FOLFOX方案肝动脉灌注化疗的研究进展[J]. 岭南现代临床外科, 2023, 23(04): 347-352.

References

[1] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021,71(3):209-249.
[2] Clark T, Maximin S, Meier J, et al.Hepatocellular Carcinoma: Review of Epidemiology, Screening, Imaging Diagnosis, Response Assessment, and Treatment[J]. Curr Probl Diagn Radiol, 2015,44(6):479-486.
[3] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132.
[4] European Association for the Study of the Liver, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018,69(1):182-236.
[5] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华肝脏病杂志, 2022,30(4):367-388.
[6] Benson AB, D'Angelica MI, Abbott DE, et al. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019[J]. J Natl Compr Canc Netw, 2019,17(4):302-310.
[7] Nagai H, Kanayama M, Higami K, et al.Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma[J]. World J Gastroenterol, 2007,13(2):280-284.
[8] Obi S, Sato S, Kawai T.Current Status of Hepatic Arterial Infusion Chemotherapy[J]. Liver Cancer, 2015,4(3):188-199.
[9] Kudo M, Matsui O, Izumi N, et al.JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan[J]. Liver Cancer, 2014,3(3-4):458-468.
[10] He MK, Le Y, Li QJ, et al.Hepatic artery infusion chemotherapy using mFOLFOX versus transarterialchemoembolization for massive unresectable hepatocellular carcinoma: aprospective non-randomized study[J]. Chin J Cancer, 2017,36(1):83.
[11] Lyu N, Lin Y, Kong Y, et al.FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]. Gut, 2018,67(2):395-396.
[12] Lewandowski RJ, Geschwind JF, Liapi E, et al.Transcatheter intraarterial therapies: rationale and overview[J]. Radiology, 2011,259(3):641-657.
[13] 秦叔逵,曹梦苒,钱军华,等. 奥沙利铂为主的FOLFOX方案治疗晚期原发性肝癌[J]. 临床肿瘤学杂志, 2005, 10(1):58-60.
[14] 伍隽华,谭慧敏,左超海,等. TACE 治疗预防肝癌术后复发的临床分析[J]. 岭南现代临床外科,2021,21(4):397-404.
[15] 张俊凯, 潘佩玲, 吴颖猛, 等. FOLFOX 6方案治疗晚期原发性肝癌的临床观察[J]. 临床肿瘤学杂志, 2010,15(1):70-74.
[16] Qin S, Bai Y, Lim HY, et al.Randomized, multicenter, open-label study of oxaliplatin plusfluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013,31(28):3501-3508.
[17] 鲜林峰, 方乐天, 刘文斌, 等. 原发性肝癌流行现状、主要发病机制及防控策略[J]. 中国癌症防治杂志, 2022,14(3):320-328.
[18] Tashiro T, Kawada Y, Sakurai Y, et al.Antitumor activity of a new platinum complex, oxalato(trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data[J]. Biomed Pharmacother, 1989,43(4):251-260.
[19] Raymond E, Faivre S, Chaney S, et al.Cellular and molecular pharmacology of oxaliplatin[J]. Mol Cancer Ther, 2002,1(3):227-235.
[20] Kalanxhi E, Meltzer S, Schou JV, et al.Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer[J]. Br J Cancer, 2018,118(10):1322-1328.
[21] Graham J, Mushin M, Kirkpatrick P.Oxaliplatin[J]. Nat Rev Drug Discov, 2004,3(1):11-12.
[22] Bleiberg H.Oxaliplatin (L-OHP): a new reality in colorectal cancer[J]. Br J Cancer, 1998,77(Suppl 4):1-3.
[23] Lyu N, Kong Y, Mu L, et al.Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018,69(1):60-69.
[24] Hu J, Bao Q, Cao G, et al.Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis[J]. Cardiovasc Intervent Radiol, 2020,43(7):996-1005.
[25] Li QJ, He MK, Chen HW, et al.Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial[J]. J Clin Oncol, 2022,40(2):150-160.
[26] Trevisani F, De Notariis S, Rossi C, et al.Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies?[J]. J Clin Gastroenterol, 2001,32(5):383-389.
[27] Liu BJ, Gao S, Zhu X, et al.Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma[J]. World J Gastrointest Oncol, 2020,12(6):663-676.
[28] Huang J, Huang W, Zhan M, et al.Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-BasedHepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma[J]. J Hepatocell Carcinoma, 2021,8:1445-1458.
[29] Luo L, Xiao Y, Zhu G, et al.Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosinekinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medicalcenter experience[J]. Front Oncol, 2022,12:1004652.
[30] He MK, Liang RB, Zhao Y, et al.Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versuslenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2021,13:17552544.
[31] Mei J, Tang YH, Wei W, et al.Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced HepatocellularCarcinoma[J]. Front Oncol, 2021,11:618206.
[32] 蒋富强, 杜鹏, 张嘉诚. FOLFOX4方案肝动脉灌注化疗联合~(125)I粒子植入治疗原发性肝癌合并Ⅲ型门静脉癌栓患者的疗效与安全性研究[J]. 中国医师进修杂志, 2022,45(5):415-421.
[33] Wang J, Zheng Z, Wu T, et al.Hepatic Arterial Infusion Chemotherapy as a Timing Strategy for Conversion Surgery to Treat Hepatocellular Carcinoma: A Single-Center Real-World Study[J]. J Hepatocell Carcinoma, 2022,9:999-1010.
[34] Pan Y, Mei J, Chen J, et al.Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant HepaticArterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma[J]. Ann Surg Oncol, 2022,29(3):2016-2029.
[35] Li SH, Mei J, Cheng Y, et al.Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study[J]. J Clin Oncol, 2022, 41(10):1898-1908.
[36] Lyu N, Wang X, Li JB, et al.Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenibin Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)[J]. J Clin Oncol, 2022,40(5):468-480.
[37] Hsu S J, Xu X, Chen MP, et al.Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization[J]. Acad Radiol, 2021,28(Suppl 1):S157-S166.
[38] Huang Y, Zhang L, He M, et al.Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials[J]. Technol Cancer Res Treat, 2022,21:2081108019.
[39] Zhang H, Zeng X, Peng Y, et al.Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma[J]. Front Pharmacol, 2022,13:849189.
[40] Sinn DH, Choi GS, Park HC, et al.Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients[J]. PLoS One, 2019,14(1):e210730.
[41] Wang T, Dong J, Zhang Y, et al.Efficacy and safety of hepatic artery infusion chemotherapy with mFOLFOX in primary liver cancer patients with hyperbilirubinemia and ineffective drainage: aretrospective cohort study[J]. Ann Transl Med, 2022,10(7):411.
[42] He M, Li Q, Zou R, et al.Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial[J]. JAMA Oncol, 2019,5(7):953-960.
[43] 陈斌, 戴海涛, 林润, 等. 经远桡动脉入路HAIC治疗肝肿瘤的安全性和舒适性研究[J]. 中山大学学报(医学科学版), 2022,43(4):639-644.
[44] Tajiri K, Kawai K, Minemura M, et al.Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil[J]. Hepatol Res, 2015,45(7):755-763.
[45] Zaitsu J, Yamasaki T, Saeki I, et al.Serum transferrin as a predictor of prognosis for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma[J]. Hepatol Res, 2014,44(5):481-490.
[46] Zhao Y, Huang F, Liu S, et al.Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and Albumin-Bilirubin score[J]. J Cancer Res Clin Oncol, 2022, 149(8):5181-5192.